Arcturus Therapeutics, Inc.
10628 Science Center Drive
Suite 250
San Diego
CA
92121
United States
52 articles with Arcturus Therapeutics, Inc.
-
Clinical Catch-Up: January 4-8
1/11/2021
The new year began with a fairly low level of clinical trial news. Here’s a look. -
Arcturus Therapeutics to Present at Upcoming Investor Conference - Jan 06, 2021
1/6/2021
Arcturus Therapeutics Holdings Inc. announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference:
-
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
12/30/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has selected ARCT-032, an aerosolized LUNAR® mRNA-based therapeutic candidate, as a development candidate for Cystic Fibrosis (CF), a prog
-
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
12/8/2020
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of $110.00 per share.
-
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock - Dec 07, 2020
12/7/2020
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data
11/9/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and nine months ended September 30, 2020, and provide
-
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore
11/9/2020
Based on interim Phase 1/2 results, a single 7.5 µg dose of ARCT-021, along with prime-boost regimens are selected to advance into later stage global clinical trials Seroconversion in majority of participants receiving doses in the range of 5 µg to 7.5 µg; Geometric Mean Titer (GMT) levels for neutralizing antibodies in the range of convalescent plasma
-
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences - Nov 04, 2020
11/4/2020
Arcturus Therapeutics Holdings Inc. announced that the Company will be presenting at upcoming investor and scientific conferences virtually:
-
Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020
10/30/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and nine months ended Sept 30, 2020 after the market close on Nov 9 and will also provi
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
10/5/2020
LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 SAN DIEGO--( BUSINESS WIRE )-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of
-
Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference
10/1/2020
Arcturus Therapeutics Holdings Inc. announced that the Company will present virtually at the upcoming conference:
-
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
9/8/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: TIDES: Oligonucleotide and Peptide Therapeutics scientific conference
-
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
8/18/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health,
-
Clinical Catch-Up: August 10-14
8/17/2020
It was a very busy week for clinical trial updates. Here’s a look. -
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
8/11/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that all subjects in the first cohort have been dosed in the Phase 1/2 clinical study with its ARCT-021 investigational vaccine for COVID-19.
-
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
8/10/2020
COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4
-
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal OfficerNationally recognized leader in corporate life sciences transactions
8/6/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020. Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group an